Paediatric Rheumatology INternational Trials Organisation (PRINTO)
The Paediatric Rheumatology INternational Trials Organisation (PRINTO) is a not for profit, non governmental, international research network founded by Alberto Martini and Nicolino Ruperto in 1996. Including initially 14 European countries, the organization counts now on the cooperation of 1376 members from 578 centres in 85 countries worldwide. PRINTO has the goal to foster, facilitate and co-ordinate the development, conduct, analysis, and reporting of multi-centres, international clinical trials and/or outcome standardisation studies in children with paediatric rheumatic diseases (PRD).
The coordinating centre is based in Genoa.
To learn more about PRINTO click here
To download the PRINTO brochure click here
The coordinating centre is based in Genoa.
To learn more about PRINTO click here
To download the PRINTO brochure click here
IN THE SPOTLIGHT
-
13-MAR-2024
European Workshop for Rheumatology Research (EWRR) - 43rd edition
View... -
15-NOV-2021
pippo
pippo... -
02-JUN-2016
2nd Global' Conference on Myositis
Details... -
11-FEB-2016
2016 Classification criteria for MAS published in Ann Rheum Dis
Paper details... -
12-JAN-2016
Placebo meta-analysis in JIA trials published in Arthritis and Rheumatology
Paper details... -
17-DEC-2015
23rd PRES Congress in Genoa 28 Sept-1 Oct 2016!
Details... -
30-NOV-2015
New EMA JIA scientific guideline adopted and published
Official Guideline...
PROJECTS
-
Learn MoreLiaisons with pharmaceutical companiesPRINTO is working with pharmaceutical companies as advisor for trials planning, centre selection, data collection, data analysis and interpretation… -
Learn MoreThe STARS TrialThe comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS trial (STARS) is a new interventional trial aiming to investigate whether an early aggressive therapeutic intervention in children with JIA, based on the initial start of synthetic and biologic DMARDs (Step-down strategy), is superior to an approach based on treatment escalation conducted following the treat-to-target principle (Step-up strategy). -
Learn MoreJuvenile dermatomyositis trialPRINTO designed the present study as a 5-year phase III single-blind, randomized clinical trial in children with newly diagnosed JDM: prednisone (PDN) versus PDN plus methotrexate, versus PDN plus Cyclosporine A… -
Learn More
The PReS Autoinflammatory Diseases’ Working Group, in collaboration with PRINTO, set up a a web-based international registry for Autoinflammatory diseases. -
Learn More
PRINTO and PRES are conducting a pharmacovigilance project which aims at observing children with JIA for 3-10 years undergoing treatment with MTX or biologic agents in order to collect moderate, severe or serious adverse events occurred. -
Learn More
PRINTO is cross-culturally adapting and validating a questionnaire which aims to enable a multidimensional assessment of the disease status and quality of life of children with JIA: the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). -
Learn More
PRINTO collected samples of children with JIA newly treated with adalimumab, etanercept or tocilizumab within the project ABIRISK, funded by IMI, which has the aim to investigate antidrug antibody formation in the treatment with biopharmaceuticals -
Learn More
The “Single Hub and Access point for paediatric Rheumatology in Europe” (SHARE) is a European project whose main objective is to improve the quality of care of patients suffering from Paediatric Rheumatic Diseases. -
Learn MoreCEST-JIAThe study is aimed to evaluate, through a pragmatic trial, safety and efficacy of switching from the adalimumab and etanercept originator molecules versus their biosimilar competitors and vice-versa in children with JIA in clinical remission on anti-TNF medication.
CERTIFICATIONS
